Literature DB >> 27790864

Upregulation of LncRNA-HIT promotes migration and invasion of non-small cell lung cancer cells by association with ZEB1.

Xiaojing Jia1, Zhicheng Wang2, Ling Qiu1, Yanming Yang1, Yunlong Wang1, Zhishen Chen1, Zhongshan Liu1, Lei Yu1.   

Abstract

Lung cancer is the most common solid tumor and the leading cause of cancer-related mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer cases. The main reason of lung cancer-related deaths is due to tumor metastasis. But, the mechanisms of NSCLC metastasis remains poorly understood. LncRNAs play pivotal roles in multiple biological processes. LncRNA-HIT (HOXA transcript induced by TGFβ) was recently identified. LncRNA-HIT promotes cell migration, invasion, tumor growth, and metastasis. However, the detailed role of lncRNA-HIT in NSCLC remains unknown. In this study, for the first time, we revealed a novel role of lncRNA-HIT in the migration and invasion of NSCLC cells. The expression of lncRNA-HIT was significantly upregulated in NSCLC tissues and cell lines, and the expression level of lncRNA-HIT correlates with advanced disease stage and predicts unfavorable prognosis of NSCLC patients. Functional assays demonstrated that lncRNA-HIT markedly increased the ability of NSCLC cells to migrate and invade. Furthermore, the molecular mechanism by which lncRNA-HIT affects NSCLC cells was associated with regulation of ZEB1 stability. LncRNA-HIT functions as a prometastasis oncogene by directly associating with ZEB1 to regulate NSCLC. The interaction of lncRNA-HIT and ZEB1 may be a potential target for NSCLC therapy.
© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990lncRNA-HITzzm321990; Invasion; ZEB1; lncRNA; migration; non-small cell lung cancer

Mesh:

Substances:

Year:  2016        PMID: 27790864      PMCID: PMC5224854          DOI: 10.1002/cam4.948

Source DB:  PubMed          Journal:  Cancer Med        ISSN: 2045-7634            Impact factor:   4.452


Introduction

Lung cancer is the most common solid tumor and the leading cause of cancer‐related mortality worldwide 1, 2.Non‐small cell lung cancer (NSCLC), including squamous cell carcinoma, adenocarcinoma, adenosquamous cell carcinoma, and large cell carcinoma, accounts for approximately 80% of all lung cancer cases 3. Despite the recent advancements of the diagnosis and treatment of NSCLC, the prognosis of patients with lung cancer remains poor 4. The main reason of lung cancer‐related deaths is due to tumor metastasis 5. However, the invasion and metastasis of NSCLC greatly limit treatment options, and no effective therapy for NSCLC patients with distant metastasis is currently available. Therefore, understanding the mechanisms of NSCLC metastasis and identification of novel therapeutic targets are urgently needed. Long noncoding RNAs (lncRNAs) are defined as a set of RNAs larger than 200 nt in length and without protein‐coding potential. LncRNAs play pivotal roles in multiple biological processes, such as chromatin remodeling, transcriptional control, posttranscriptional regulation, and intercellular signaling 6, 7. A growing number of studies have reported that the dysregulation of lncRNAs expression was involved in many cancers including lung cancer 8, 9. Some lncRNAs have been demonstrated to play important roles in lung carcinogenesis and have emerged as biomarkers for tumor diagnosis and prediction of prognosis 10, 11, 12. LncRNA‐HIT (HOXA transcript induced by TGFβ) was recently identified 13. LncRNA‐HIT regulates TGF‐β‐induced epithelial‐to‐mesenchymal transition (EMT). Knockdown of lncRNA‐HIT resulted in decreasing of cell migration, invasion, tumor growth, and metastasis 13. However, the detailed role of lncRNA‐HIT in NSCLC remains unknown. In this study, we elucidated the clinical significance of lncRNA‐HIT on the prognosis and clinicopathological characteristics of NSCLC patients. We also focused on the underlying molecular mechanisms by which lncRNA‐HIT promotes migration and invasion of NSCLC cells.

Material and Methods

Cell culture and samples

Five NSCLC cell lines (SK‐MES‐1, NCI‐H1650, A549, NCI‐H1975, 95D) and normal lung epithelial cells (NLEC) were purchased from ATCC. The cells were cultured in Dulbecco's modified eagle's medium (DMEM) containing 10% fetal bovine serum (FBS) at 37°C in 5% CO2. The tumor tissues and patient data were obtained from The Second Hospital of Jilin University. All of the patients were provided written informed consent.

Viral infections

LncRNA‐HIT cDNA was cloned into the pLVX lentiviral vector (Addgene, Cambridge, MA). Virus was made using Turbofect transfection (Thermo, Boston, MA) into 293T cells. Virus was filtered and then infected into cells with polybrene for 24 h. Cells were selected with 3 μg/mL puromycin (Invitrogen, Carlsbad, CA). The pLKO.1 shRNA lentiviral system was used to knockdown genes of interest. pLKO.1, pLKO.1‐shHIT‐1, and pLKO.1‐shHIT‐2 were purchased from Genechem Company, Shanghai, China. Target sequences for shRNAs are as follows: shHIT‐1: GTCTCACATACCTTCCTAACTCTAG, shHIT‐2: CCTCCAAGGTGGTCTGTGACCTTAA. Puromycin at 3 μg/mLwas used to select stable cells.

Western blot

Western blotting was performed as described previously 14. Primary antibodies 1:1000 anti‐ZEB1 (Abcam), 1:1000 anti‐E‐cadherin (CST),1:1000 anti‐ZO1 (CST), 1:1000 anti‐N‐cadherin (CST), 1:1000 antivimentin (CST), and 1:10000 anti‐GAPDH (Santa Cruz) were used. Secondary detection antibodies were anti‐mouse IgG‐HRP conjugate (Jackson) used at 1:10000 or anti‐rabbit IgG–HRP conjugate (Jackson). Blots were developed with ECL substrate (Millipore Boston, MA) and analyzed on an imager (GE Healthcare, London, UK).

Migration and invasion assays

A total of 5 × 104 cells were seeded in a serum‐free DMEM in the upper chamber of a 24‐well transwell migration or invasion insert (BD biosciences, Franklin lakes, NJ). The lower chamber was filled with medium containing 20% FBS. After 24 h of culture at 37°C, cells in the upper chamber were removed, and the cells that had traversed the membrane were fixed in 4% paraformaldehyde, and then stained by crystal violet.

RNA isolation and quantitative real‐time PCR (qRT‐PCR)

Total RNAs of cells or tissue samples were isolated using TRIzol (Invitrogen) according to the manufacturers’ instructions. First‐strand cDNA was generated using the Reverse Transcriptase (Transgene, Beijing, China). qRT‐PCR was performed in the ABI 7500 Real‐Time PCR System using SYBR Green Mixture (Takara, Dalian, China). Data were normalized to GAPDH or to control samples. Primers sequences for the target genes were as follows: lncRNA‐HIT‐F: 5′‐TGAAA_GGGAGAGAAAGGAAAGG‐3′, lncRNA‐HIT‐R: 5′‐GACAGTCTAGGCATTGCTGAT‐3′; ZEB1‐F: 5′‐CCCAGGACAGCACAGTAAAT‐3′, ZEB1‐R: 5′‐GATGGTGTACTACTTCTGGAACC‐3′.

RNA immunoprecipitation assay

RNA immunoprecipitation assay (RIP) assays were performed as described previously 15. RIP products were analyzed by qRT‐PCR. A total quantity of 5 μg Snail1 (Abcam), Snail2 (Abcam), ZEB1 (Abcam), ZEB2 (Abcam), Twist1 (Abcam), or Twist2 (Abcam) antibodies were used for RIP reaction.

Chromatin immunoprecipitation assay (ChIP)

ChIP assays were performed as described previously 16. The primers for the CDH1 promoter were as follows: 5′‐ACTCCAGGCTAGAGGGTCACC‐3′ (sense) and 5′‐CCGCAAGCTCACAGGTGCTTTGCAGTTCC‐3′ (antisense).

RNA pull‐down assay

RNA pull‐down and deletion mapping were performed as described previously 15. Briefly, biotin‐labeled lncRNA‐HIT were in vitro transcribed with the Biotin RNA Labeling Mix (Roche, Cambridge, UK) and T7 RNA polymerase (Roche), treated with RNase‐free DNase I (Roche), and purified with the RNeasy Mini Kit (Qiagen, Dusseldolf, Germany). Cell nuclear proteins were extracted using the Cytoplasmic and Nuclear Protein Extraction Kit (Tiangen, Beijing China). Cell nuclear extract was then mixed with biotin‐labeled lncRNA‐HIT. Washed streptavidin agarose beads (Invitrogen) were added to each binding reaction and further incubated at room temperature. Beads were washed briefly five times and boiled in sodium dodecyl sulfate buffer, and the retrieved protein was detected by the standard western blotting.

Statistics

All experiments were repeated at least three times. Results are expressed as mean ± SD as indicated. A two‐tailed Student's t test was used for intergroup comparisons. P < 0.05 was considered statistically significant.

Results

lncRNA‐HIT is upregulated in NSCLC tissues and cell lines

We first examined the expression level of lncRNA‐HIT in NSCLC tissues and cell lines using qRT‐PCR. The results showed that the expression of lncRNA‐HIT of five NSCLC cell lines, namely SK‐MES‐1, NCI‐H1650, A549, NCI‐H1975, and 95D, was significantly higher than normal lung epithelial cells (NLEC) (Fig. 1A). In parallel, lncRNA‐HIT expression was markedly increased in NSCLC tumor tissues (T) compared to matched adjacent nontumor tissues (NT) from 60 patients with NSCLC (P<0.001) (Fig. 1B). Taken together, these data suggest that lncRNA‐HIT expression is upregulated in NSCLC.
Figure 1

lnc is upregulated in NSCLC tissues and cell lines and correlates with prognosis.(A) The relative expression of lnc in different NSCLC cell lines and normal lung epithelial cells (NLEC). (B) The relative expression of lnc in NSCLC tumor tissues (T) compared to matched adjacent nontumor tissues (NT) from 60 NSCLC patients. (C) Kaplan–Meier analyses of the correlations between lncRNA‐HIT expression level and overall survival of 60 patients with NSCLC. The cut point of high and low LncRNA‐HIT expressers is the median. Data are shown as mean ± SD. *P < 0.05

lnc is upregulated in NSCLC tissues and cell lines and correlates with prognosis.(A) The relative expression of lnc in different NSCLC cell lines and normal lung epithelial cells (NLEC). (B) The relative expression of lnc in NSCLC tumor tissues (T) compared to matched adjacent nontumor tissues (NT) from 60 NSCLC patients. (C) Kaplan–Meier analyses of the correlations between lncRNA‐HIT expression level and overall survival of 60 patients with NSCLC. The cut point of high and low LncRNA‐HIT expressers is the median. Data are shown as mean ± SD. *P < 0.05

High‐level expression of lncRNA‐HIT correlates with advanced disease stage and predicts unfavorable prognosis

To investigate the clinical significance of lncRNA‐HIT in NSCLC, the correlation between lncRNA‐HIT expression and clinicopathological features were analyzed (Table 1). LncRNA‐HIT expression significantly correlated with the clinical staging (P = 0.02) and distant metastasis (P = 0.002). Furthermore, Kaplan–Meier analysis showed that NSCLC patients with high‐level lncRNA‐HIT expression group had a shorter median survival time than those in the low‐level group (Fig. 1C). These results suggested that lncRNA‐HIT expression may be a novel valuable marker for the prognosis of NSCLC patients.
Table 1

The relationship between lncRNA‐HIT expression and the clinicopathological characteristics of Non‐Small Cell Lung Cancer (NSCLC) patients

Features lncRNAHIT P‐value
LowHigh
Age
≤6023210.559
>6079
Gender
Male24230.754
Female67
Histology
Squamous cell carcinoma1090.898
Adenocarcinoma1312
Adenosquamous carcinoma23
Bronchioalveolar carcinoma56
Clinical stage
I, II20110.02
III, IV1019
Distant metastasis
No2190.002
Yes921
Drug/radiation therapy
No9100.781
Yes2120

P‐values were derived with a two‐sided Pearson chi‐square test.

The relationship between lncRNA‐HIT expression and the clinicopathological characteristics of Non‐Small Cell Lung Cancer (NSCLC) patients P‐values were derived with a two‐sided Pearson chi‐square test.

Silence of lncRNA‐HIT inhibits the migration and invasion of NSCLC cells

Based on the above results, we hypothesized a relationship between lncRNA‐HIT and NSCLC cell migration and invasion. To determine the role of lncRNA‐HIT in NSCLC cell migration and invasion, we silenced lncRNA‐HIT expression using lentivirus‐mediated shRNAs in A549 and SK‐MES‐1 cells (Fig. 2A). Notably, lncRNA‐HIT depletion significantly reduced the expression of mesenchymal markers, N‐cadherin and vimentin, and increased the expression of epithelial markers, E‐cadherin and ZO‐1 (Fig. 2B). The migration assay showed that lncRNA‐HIT knockdown inhibited the migratory capabilities of both A549 and SK‐MES‐1 cells compared to their control cells (Fig. 2C). Moreover, lncRNA‐HIT‐silenced NSCLC cells showed much weaker abilities to invade through Matrigel than did control cells (Fig. 2D).
Figure 2

Silence of lnc inhibits the migration and invasion of NSCLC cells. (A) The relative expression of lnc in control and lnc knockdown cells. (B) The EMT markers detected by western blot in control and lnc knockdown cells. (C) Knockdown of lnc suppressed migration in NSCLC cells. (D) Knockdown of lnc suppressed invasion in NSCLC cells. Data are shown as mean ± SD . *P < 0.05. EMT, epithelial‐to‐mesenchymal transition.

Silence of lnc inhibits the migration and invasion of NSCLC cells. (A) The relative expression of lnc in control and lnc knockdown cells. (B) The EMT markers detected by western blot in control and lnc knockdown cells. (C) Knockdown of lnc suppressed migration in NSCLC cells. (D) Knockdown of lnc suppressed invasion in NSCLC cells. Data are shown as mean ± SD . *P < 0.05. EMT, epithelial‐to‐mesenchymal transition.

Overexpression of lncRNA‐HIT promotes the migration and invasion of NSCLC cells

In contrast, gain‐of‐function of lncRNA‐HIT with lentivirus‐mediated overexpression was performed to evaluate whether ectopic lncRNA‐HIT expression promotes the invasiveness of NSCLC cells (Fig. 3A). Overexpression of lncRNA‐HIT significantly inhibited the expression of epithelial markers, E‐cadherin and ZO‐1, and increased the expression of mesenchymal markers, N‐cadherin and vimentin (Fig. 3B). In addition, overexpression of lncRNA‐HIT obviously promoted the migratory and invasive abilities of both A549 and SK‐MES‐1 cells (Fig. 3C and 3D). Taken together, these data demonstrated that lncRNA‐HIT promotes EMT and remarkably induces the invasive phenotype of NSCLC cell lines.
Figure 3

Overexpression of lnc promotes the migration and invasion of NSCLC cells. (A) The relative expression of lnc in control and lnc overexpressed cells. (B) The EMT markers detected by western blot in control and lnc overexpressed cells. (C) Overexpression of lnc promoted migration in NSCLC cells. (D) Overexpression of lnc promoted invasion in NSCLC cells. Data are shown as mean ± SD. *P < 0.05. EMT, epithelial‐to‐mesenchymal transition.

Overexpression of lnc promotes the migration and invasion of NSCLC cells. (A) The relative expression of lnc in control and lnc overexpressed cells. (B) The EMT markers detected by western blot in control and lnc overexpressed cells. (C) Overexpression of lnc promoted migration in NSCLC cells. (D) Overexpression of lnc promoted invasion in NSCLC cells. Data are shown as mean ± SD. *P < 0.05. EMT, epithelial‐to‐mesenchymal transition.

LncRNA‐HIT associates with ZEB1

Suppression of E‐cadherin, induced by Snail, ZEB, or Twist family, is considered not only a hallmark of EMT but also a key driver of EMT and metastasis 17. We suspected that whether lncRNA‐HIT regulates E‐cadherin expression through association with these EMT‐related transcription repressors. We detected the association between lncRNA‐HIT and these repressors by performing RIP assays. The results showed that lncRNA‐HIT was significantly enriched by ZEB1 antibody than the nonspecific IgG control antibody, Snail1, Snail2, ZEB2, Twist1, or Twist2 antibody (Fig. 4A). To validate the association and determine the specific binding region between lncRNA‐HIT and ZEB1, we performed RNA pull‐down assay and deletion‐mapping experiments. We found a 423‐nt region at the 5′ end of lncRNA‐HIT required for the association with ZEB1 (Fig. 4B). Taken together, we demonstrated a specific association between lncRNA‐HIT and ZEB1.
Figure 4

lnc associates with ZEB1. (A) RIP assays for lnc were performed using indicated antibodies. (B) Deletion mapping of ZEB1‐binding domain in lnc (Up). Western blot for ZEB1 in samples pulled down by different lnc fragments (Down). Antisense lnc was used as a negative control. (C) The relative ZEB1 mRNA expression in control and lnc knockdown cells. (D) The ZEB1 protein level in control and lnc knockdown cells. (E) The relative ZEB1 mRNA expression in control and lnc overexpressed cells. (F) The ZEB1 protein level in control and lnc overexpressed cells. (G) The stability of ZEB1 protein over time was measured by western blot relative to time 0 after blocking new protein synthesis with 100 mg/ml CHX in control and lnc knockdown A549 cells. (H) ZEB1 protein expression in control and lnc knockdown A549 cells treated with vehicle control (DMSO) or 10 μmol/L MG132 for 12 h. (I) The occupancy of ZEB1 in the promoter of was measured by ZEB1 ChIP assay followed by qRT‐PCR in control and lnc knockdown A549 cells. (J) The occupancy of ZEB1 in the promoter of was measured by ZEB1 ChIP assay followed by qRT‐PCR in control and lnc overexpressed A549 cells. Data are shown as mean ± SD. *P < 0.05. RIP, RNA immunoprecipitation assay

lnc associates with ZEB1. (A) RIP assays for lnc were performed using indicated antibodies. (B) Deletion mapping of ZEB1‐binding domain in lnc (Up). Western blot for ZEB1 in samples pulled down by different lnc fragments (Down). Antisense lnc was used as a negative control. (C) The relative ZEB1 mRNA expression in control and lnc knockdown cells. (D) The ZEB1 protein level in control and lnc knockdown cells. (E) The relative ZEB1 mRNA expression in control and lnc overexpressed cells. (F) The ZEB1 protein level in control and lnc overexpressed cells. (G) The stability of ZEB1 protein over time was measured by western blot relative to time 0 after blocking new protein synthesis with 100 mg/ml CHX in control and lnc knockdown A549 cells. (H) ZEB1 protein expression in control and lnc knockdown A549 cells treated with vehicle control (DMSO) or 10 μmol/L MG132 for 12 h. (I) The occupancy of ZEB1 in the promoter of was measured by ZEB1 ChIP assay followed by qRT‐PCR in control and lnc knockdown A549 cells. (J) The occupancy of ZEB1 in the promoter of was measured by ZEB1 ChIP assay followed by qRT‐PCR in control and lnc overexpressed A549 cells. Data are shown as mean ± SD. *P < 0.05. RIP, RNA immunoprecipitation assay Next, we determined the function of lncRNA‐HITZEB1 association. Silence of lncRNA‐HIT significantly suppressed the protein level of ZEB1, but had no effect on the ZEB1 mRNA level (Fig. 4C and D). In contrast, overexpression of lncRNA‐HIT increased the protein level, but not mRNA level, of ZEB1 (Fig. 4E and F). These results strongly indicated that the association of lncRNA‐HIT and ZEB1 may influence the stability of ZEB1 protein. To further confirm the lncRNA‐HIT‐mediated ZEB1 regulation, we treated control and lncRNA‐HIT knockdown A549 cells with cycloheximide (CHX). We found that the half‐life of ZEB1 was much shorter in lncRNA‐HIT knockdown A549 cells than that in control cells (Fig. 4G). When MG132, an inhibitor of proteasome degradation was used, the ZEB1 protein level in lncRNA‐HIT knockdown A549 cells was markedly upregulated and reached a level that was comparable to that in control cells (Fig. 4H). Taken together, these data suggested that lncRNA‐HIT is important for the stability of ZEB1 protein. Next, we examined whether lncRNA‐HIT affected ZEB1 occupancy of the promoter region in CDH1. The effect of lncRNA‐HIT on the ZEB1 occupancy of CDH1 promoter was evaluated using a ChIP assay followed by qPCR. We found that overexpression of lncRNA‐HIT significantly increased the occupancy of ZEB1 on the promoter region of CDH1, while silence of lncRNA‐HIT reduced the binding of ZEB1 on the CDH1 promoter (Fig. 4I and J).

LncRNA‐HIT promotes migration and invasion via regulation of ZEB1 expression

Finally, we determined whether lncRNA‐HIT promotes migration and invasion via regulation of ZEB1 expression. We found that overexpression of ZEB1 (Fig. 5A) significantly rescued the cell migration and invasion phenotypes induced by lncRNA‐HIT knockdown (Fig. 5B and C). Together, these results demonstrate that lncRNA‐HIT exerts its function at least in part through regulating ZEB1 expression.
Figure 5

lnc promotes migration and invasion via regulation of ZEB1 expression. (A) ZEB1 protein expression in A549 control and lnc knockdown cells expressing control and ZEB1. (B) Migration of A549 cells expressing control and lnc shRNAs with and without ZEB1. (C) Invasion of A549 cells expressing control and lnc shRNAs with and without ZEB1. Data are shown as mean ± SD. *P < 0.05.

lnc promotes migration and invasion via regulation of ZEB1 expression. (A) ZEB1 protein expression in A549 control and lnc knockdown cells expressing control and ZEB1. (B) Migration of A549 cells expressing control and lnc shRNAs with and without ZEB1. (C) Invasion of A549 cells expressing control and lnc shRNAs with and without ZEB1. Data are shown as mean ± SD. *P < 0.05.

Discussion

In this study, for the first time, we revealed a novel role of lncRNA‐HIT in the migration and invasion of NSCLC cells. The expression of lncRNA‐HIT was significantly upregulated in NSCLC tissues and cell lines, and the expression level of lncRNA‐HIT correlates with advanced disease stage and predicts unfavorable prognosis of NSCLC patients. Silence of lncRNA‐HIT effectively decreased the migration and invasion of NSCLC cells. In contrast, the overexpression of lncRNA‐HIT markedly increased the ability of NSCLC cells to migrate and invade. The molecular mechanism by which lncRNA‐HIT affects NSCLC cells was associated with regulation of ZEB1 stability. lncRNA‐HIT may function as a prometastasis oncogene by directly associating with ZEB1 to regulate NSCLC. Many large‐scale sequencing studies have demonstrated that >9000 genomic loci express lncRNAs 18, 19. However, the vast majority of these lncRNAs remain functionally uncharacterized in NSCLC. Increasing evidence suggests that lncRNAs play important roles in oncogenesis and metastasis in NSCLC. For example, lncRNA AGAP2AS1 promotes NSCLC growth through interacting with EZH2 and LSD1 and repressing LATS2 and KLF2 expression 8. LncRNA TATDN1 promotes NSCLC metastasis through suppression of E‐cadherin 20. These and other examples suggest that lncRNAs are critical to many oncogenic processes. lncRNA‐HIT, an oncogene, has been documented to promote tumor metastasis in breast cancer 13. However, the role of lncRNA‐HIT in NSCLC remains unclear. We first analyzed the expression of lncRNA‐HIT on the NSCLC tissues cell lines. LncRNA‐HIT was significantly upregulated, correlates with advanced disease stage, and predicts unfavorable prognosis, indicating that lncRNA‐HIT may play an important role in NSCLC invasion and metastasis. Functional assays demonstrated an important role of lncRNA‐HIT in NSCLC progression, including migration and invasion. Mechanistic study revealed that lncRNA‐HIT exerts prometastasis function at least in part through association with ZEB1. ZEB factors contain multiple domains to interact with other transcription factors, which is essential for regulation of EMT. For example, ZEB proteins can recruit histone deacetylases, methyltransferases, and polycomb group proteins 21, 22, 23. ZEB1 also suppressed transcription through recruitment of the SWI/SNF chromatin remodeling ATPase BRG1 24. Recent studies have found a set of lncRNA that can regulate ZEB1 expression through sponging miRNAs, such as lncRNA‐ATB and lncRNA‐NEAT1 25, 26. In this study, for the first time, we revealed a novel posttranslational manner, in which lncRNA regulates ZEB1. We found that lncRNA‐HIT could evaluate the stability of ZEB1 and then increase the ZEB1 occupancy of the promoter region in CDH1. The interaction of lncRNA‐HIT and ZEB1 may be a potential target for NSCLC therapy. Overall, our study is the first to show that lncRNA‐HIT plays an important role in metastasis in NSCLC. LncRNA‐HIT promotes cell migration and invasion at least in part through interaction with ZEB1 regulating its expression. However, it should be pointed out that our in vitro observations may not be completely applied to in vivo situations in the absence of in vivo studies. The possible role of lncRNA‐HIT in NSCLC required further studies using animal models of tumors.

Conflict of Interest

None declared.
  26 in total

1.  Coordinated histone modifications mediated by a CtBP co-repressor complex.

Authors:  Yujiang Shi; Jun-ichi Sawada; Guangchao Sui; El Bachir Affar; Johnathan R Whetstine; Fei Lan; Hidesato Ogawa; Margaret Po-Shan Luke; Yoshihiro Nakatani; Yang Shi
Journal:  Nature       Date:  2003-04-17       Impact factor: 49.962

2.  A novel long noncoding RNA LINC01133 is upregulated in lung squamous cell cancer and predicts survival.

Authors:  Jing Zhang; Ning Zhu; Xiaodong Chen
Journal:  Tumour Biol       Date:  2015-04-24

3.  LncRNA-UCA1 exerts oncogenic functions in non-small cell lung cancer by targeting miR-193a-3p.

Authors:  Wei Nie; Hui-juan Ge; Xiao-qun Yang; Xiangjie Sun; Hai Huang; Xia Tao; Wan-sheng Chen; Bing Li
Journal:  Cancer Lett       Date:  2015-12-03       Impact factor: 8.679

Review 4.  LncRNAs, lost in translation or licence to regulate?

Authors:  Alvaro de Andres-Pablo; Antonin Morillon; Maxime Wery
Journal:  Curr Genet       Date:  2016-05-26       Impact factor: 3.886

Review 5.  Classification and Pathology of Lung Cancer.

Authors:  Min Zheng
Journal:  Surg Oncol Clin N Am       Date:  2016-07       Impact factor: 3.495

Review 6.  Epidemiology of Lung Cancer.

Authors:  Yousheng Mao; Ding Yang; Jie He; Mark J Krasna
Journal:  Surg Oncol Clin N Am       Date:  2016-07       Impact factor: 3.495

Review 7.  The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016.

Authors:  Daniel S W Tan; Sue S Yom; Ming S Tsao; Harvey I Pass; Karen Kelly; Nir Peled; Rex C Yung; Ignacio I Wistuba; Yasushi Yatabe; Michael Unger; Philip C Mack; Murry W Wynes; Tetsuya Mitsudomi; Walter Weder; David Yankelevitz; Roy S Herbst; David R Gandara; David P Carbone; Paul A Bunn; Tony S K Mok; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2016-05-23       Impact factor: 15.609

Review 8.  Epithelial-to-Mesenchymal Transition in Diabetic Nephropathy: Fact or Fiction?

Authors:  Ivonne Loeffler; Gunter Wolf
Journal:  Cells       Date:  2015-10-09       Impact factor: 6.600

9.  The ratio of FoxA1 to FoxA2 in lung adenocarcinoma is regulated by LncRNA HOTAIR and chromatin remodeling factor LSH.

Authors:  Ranran Wang; Ying Shi; Ling Chen; Yiqun Jiang; Chao Mao; Bin Yan; Shuang Liu; Bin Shan; Yongguang Tao; Xiang Wang
Journal:  Sci Rep       Date:  2015-12-11       Impact factor: 4.379

10.  Landscape of transcription in human cells.

Authors:  Sarah Djebali; Carrie A Davis; Angelika Merkel; Alex Dobin; Timo Lassmann; Ali Mortazavi; Andrea Tanzer; Julien Lagarde; Wei Lin; Felix Schlesinger; Chenghai Xue; Georgi K Marinov; Jainab Khatun; Brian A Williams; Chris Zaleski; Joel Rozowsky; Maik Röder; Felix Kokocinski; Rehab F Abdelhamid; Tyler Alioto; Igor Antoshechkin; Michael T Baer; Nadav S Bar; Philippe Batut; Kimberly Bell; Ian Bell; Sudipto Chakrabortty; Xian Chen; Jacqueline Chrast; Joao Curado; Thomas Derrien; Jorg Drenkow; Erica Dumais; Jacqueline Dumais; Radha Duttagupta; Emilie Falconnet; Meagan Fastuca; Kata Fejes-Toth; Pedro Ferreira; Sylvain Foissac; Melissa J Fullwood; Hui Gao; David Gonzalez; Assaf Gordon; Harsha Gunawardena; Cedric Howald; Sonali Jha; Rory Johnson; Philipp Kapranov; Brandon King; Colin Kingswood; Oscar J Luo; Eddie Park; Kimberly Persaud; Jonathan B Preall; Paolo Ribeca; Brian Risk; Daniel Robyr; Michael Sammeth; Lorian Schaffer; Lei-Hoon See; Atif Shahab; Jorgen Skancke; Ana Maria Suzuki; Hazuki Takahashi; Hagen Tilgner; Diane Trout; Nathalie Walters; Huaien Wang; John Wrobel; Yanbao Yu; Xiaoan Ruan; Yoshihide Hayashizaki; Jennifer Harrow; Mark Gerstein; Tim Hubbard; Alexandre Reymond; Stylianos E Antonarakis; Gregory Hannon; Morgan C Giddings; Yijun Ruan; Barbara Wold; Piero Carninci; Roderic Guigó; Thomas R Gingeras
Journal:  Nature       Date:  2012-09-06       Impact factor: 49.962

View more
  17 in total

1.  New twists on long noncoding RNAs: from mobile elements to motile cancer cells.

Authors:  Tuan M Nguyen; Sumayya Alchalabi; Adewunmi Oluwatoyosi; Ali S Ropri; Jason I Herschkowitz; Jeffrey M Rosen
Journal:  RNA Biol       Date:  2020-06-10       Impact factor: 4.652

2.  lncRNA-HIT promotes cell proliferation of non-small cell lung cancer by association with E2F1.

Authors:  L Yu; F Fang; S Lu; X Li; Y Yang; Z Wang
Journal:  Cancer Gene Ther       Date:  2017-04-21       Impact factor: 5.987

Review 3.  Role of lncRNA and EZH2 Interaction/Regulatory Network in Lung Cancer.

Authors:  Min Su; Yuhang Xiao; Jinming Tang; Jie Wu; Junliang Ma; Bo Tian; Yong Zhou; Hui Wang; Desong Yang; Qian-Jin Liao; Wenxiang Wang
Journal:  J Cancer       Date:  2018-10-18       Impact factor: 4.207

4.  Upregulation of the Long Noncoding RNA SNHG3 Promotes Lung Adenocarcinoma Proliferation.

Authors:  Liang Liu; Jianjiao Ni; Xinhong He
Journal:  Dis Markers       Date:  2018-07-22       Impact factor: 3.434

5.  Long non-coding RNA urothelial cancer associated 1 can regulate the migration and invasion of colorectal cancer cells (SW480) via myocardin-related transcription factor-A.

Authors:  Long Zhang; Chengcheng Zheng; Zhen Sun; Huaqing Wang; Fengwei Wang
Journal:  Oncol Lett       Date:  2019-08-09       Impact factor: 2.967

6.  LINC-PINT alleviates lung cancer progression via sponging miR-543 and inducing PTEN.

Authors:  Shu Wang; Wenyang Jiang; Xinghua Zhang; Zilong Lu; Qing Geng; Wei Wang; Nan Li; Xinyong Cai
Journal:  Cancer Med       Date:  2020-01-25       Impact factor: 4.452

Review 7.  LncRNAs regulate cancer metastasis via binding to functional proteins.

Authors:  Liting Yang; Yanyan Tang; Fang Xiong; Yi He; Fang Wei; Shanshan Zhang; Can Guo; Bo Xiang; Ming Zhou; Ni Xie; Xiaoling Li; Yong Li; Guiyuan Li; Wei Xiong; Zhaoyang Zeng
Journal:  Oncotarget       Date:  2017-12-01

8.  Long non-coding RNAs function as novel predictors and targets of non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Yanlu Xiong; Tao Wang; Mingxing Wang; Jinbo Zhao; Xiaofei Li; Zhipei Zhang; Yongsheng Zhou; Jiabao Liu; Lintao Jia; Yong Han
Journal:  Oncotarget       Date:  2018-01-04

Review 9.  Long Non-Coding RNAs: Key Regulators of Epithelial-Mesenchymal Transition, Tumour Drug Resistance and Cancer Stem Cells.

Authors:  Richard Heery; Stephen P Finn; Sinead Cuffe; Steven G Gray
Journal:  Cancers (Basel)       Date:  2017-04-21       Impact factor: 6.639

10.  Long noncoding RNA LINC01510 promotes the growth of colorectal cancer cells by modulating MET expression.

Authors:  Chaoqun Cen; Jian Li; Jingjing Liu; Mingshi Yang; Tianyi Zhang; Yu Zuo; Changwei Lin; Xiaorong Li
Journal:  Cancer Cell Int       Date:  2018-03-21       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.